Multivariate analysis comparing intravenous formulation busulfan to TBI-based myeloablative conditioning regimens before HCT for myeloid malignancies
| Overall mortality* . | Level . | N . | HR (95% CI) . | P value . |
|---|---|---|---|---|
| Conditioning regimen | TBI | 446 | 1 | |
| IV-BU | 993 | 0.819 (0.683-0.981) | .0302 | |
| Patient age (y) | ≤19 | 199 | 1 | .0008† |
| 20-49 | 704 | 1.347 (0.989-1.836) | .0592 | |
| ≥50 | 536 | 1.727 (1.258-2.371) | .0007 | |
| Race | White | 1278 | 1 | |
| Other | 161 | 1.409 (1.084-1.831) | .0104 | |
| HCT CI | ≤3 | 1186 | 1 | |
| >3 | 253 | 1.417 (1.153-1.743) | .0009 | |
| TRM* | ||||
| Conditioning regimen | TBI | 446 | 1 | |
| IV-BU | 988 | 0.800 (0.596-1.075) | .1395 | |
| Patient age, years | ≤19 | 198 | 1 | .0167† |
| 20-49 | 701 | 1.309 (0.810-2.114) | .2710 | |
| ≥50 | 532 | 1.829 (1.123-2.979) | .0153 | |
| Race | White | 1271 | 1 | |
| Other | 160 | 1.719 (1.158-2.551) | .0072 | |
| Disease relapse* | ||||
| Conditioning regimen | TBI | 446 | 1 | |
| IV-BU | 988 | 0.933 (0.766-1.137) | .4940 | |
| HCT CI | ≤3 | 1179 | 1 | |
| >3 | 252 | 1.329 (1.050-1.683) | .0180 | |
| Treatment failure*‡ | ||||
| Conditioning regimen | TBI | 446 | 1 | |
| IV-BU | 985 | 0.894 (0.759-1.053) | .1795 | |
| HCT CI | ≤3 | 1179 | 1 | |
| >3 | 252 | 1.354 (1.119-1.638) | .0018 |
| Overall mortality* . | Level . | N . | HR (95% CI) . | P value . |
|---|---|---|---|---|
| Conditioning regimen | TBI | 446 | 1 | |
| IV-BU | 993 | 0.819 (0.683-0.981) | .0302 | |
| Patient age (y) | ≤19 | 199 | 1 | .0008† |
| 20-49 | 704 | 1.347 (0.989-1.836) | .0592 | |
| ≥50 | 536 | 1.727 (1.258-2.371) | .0007 | |
| Race | White | 1278 | 1 | |
| Other | 161 | 1.409 (1.084-1.831) | .0104 | |
| HCT CI | ≤3 | 1186 | 1 | |
| >3 | 253 | 1.417 (1.153-1.743) | .0009 | |
| TRM* | ||||
| Conditioning regimen | TBI | 446 | 1 | |
| IV-BU | 988 | 0.800 (0.596-1.075) | .1395 | |
| Patient age, years | ≤19 | 198 | 1 | .0167† |
| 20-49 | 701 | 1.309 (0.810-2.114) | .2710 | |
| ≥50 | 532 | 1.829 (1.123-2.979) | .0153 | |
| Race | White | 1271 | 1 | |
| Other | 160 | 1.719 (1.158-2.551) | .0072 | |
| Disease relapse* | ||||
| Conditioning regimen | TBI | 446 | 1 | |
| IV-BU | 988 | 0.933 (0.766-1.137) | .4940 | |
| HCT CI | ≤3 | 1179 | 1 | |
| >3 | 252 | 1.329 (1.050-1.683) | .0180 | |
| Treatment failure*‡ | ||||
| Conditioning regimen | TBI | 446 | 1 | |
| IV-BU | 985 | 0.894 (0.759-1.053) | .1795 | |
| HCT CI | ≤3 | 1179 | 1 | |
| >3 | 252 | 1.354 (1.119-1.638) | .0018 |
Model stratified by disease status (AML early vs AML intermediate vs AML advanced vs CML early vs CML intermediate vs CML advanced vs MDS early vs MDS advanced), donor type (HLA-id sib vs well-matched unrelated vs partially matched unrelated), and performance score (<90% vs ≥90%).
Overall P value.
Treatment failure is 1/relapse-free survival; events are death or disease relapse.